S029 What's New in Dermatopathology
DESCRIPTION
This symposium provides information regarding advances in key areas of dermatopathology. Cutaneous neoplasia, inflammatory skin disease, molecular techniques, computer assisted diagnosis/artificial intelligence, translational research, and cutaneous infections will be covered. Attendees will leave the session with updated knowledge in dermatopathology.
LEARNING OBJECTIVES
Describe new advances in cutaneous neoplasia, including melanocytic tumors and adnexal neoplasms
Discuss recent developments in diagnosing inflammatory skin disease and cutaneous drug reactions
Describe recent developments in artificial intelligence in the field of dermatopathology
SCHEDULE
9:00 AM
Course introduction
Jeffrey P. North, MD, FAAD
9:02 AM
Updates in Melanocytic Tumors
Iwei Yeh, MD, PhD, FAAD
9:25 AM
Updates in Psoriasis and Eczema
William Damsky, PhD, MD, FAAD
9:48 AM
Updates in Viral-induced Granulomatous Reactions
Karolyn Wanat, MD, FAAD
10:10 AM
Q&A
William Damsky, PhD, MD, FAAD, Karolyn Wanat, MD, FAAD, Iwei Yeh, MD, PhD, FAAD
10:20 AM
Updated in Pigmentary Disorders
Anisha Patel, MD, FAAD
10:43 AM
Updates in Artificial Intelligence/Computer Assisted Diagnosis
Kiran Motaparthi, MD, FAAD
11:06 AM
Newer Cutaneous Drug Reactions
Emily Y. Chu, MD, PhD, FAAD
11:30 AM
Updates in Non-melanocytic Cutaneous Tumors
Jeffrey P. North, MD, FAAD
11:50 AM
Q&A
Jeffrey P. North, MD, FAAD, Emily Y. Chu, MD, PhD, FAAD, Kiran Motaparthi, MD, FAAD, Anisha Patel, MD, FAAD
DIRECTOR
Jeffrey P. North, MD, FAAD
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
William Damsky, PhD, MD, FAAD
Kiran Motaparthi, MD, FAAD
Anisha Patel, MD, FAAD
Karolyn Wanat, MD, FAAD
Iwei Yeh, MD, PhD, FAAD
HANDOUTS
DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
William Damsky, PhD, MD, FAAD
AbbVie – Investigator(Fees); Advanced Cell Diagnostics, Inc. – Investigator(Equipment); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); CSL Behring – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Consultant(Fees); Epiarx Diagnostics – Consultant (1099 relationship)(Fees); Fresenius Kabi – Consultant (1099 relationship)(Fees); Incite – Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); MilliporeSigma – Other(Patent royalties or other compensation for Intellectual Property Rights); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); TWi Biote – Consultant (1099 relationship)(Fees); TWi Biotechnology, Inc. – Consultant(Fees), Consultant (1099 relationship)(Fees), Investigator(Fees);
Kiran Motaparthi, MD, FAAD
Castle Biosciences, Inc – Consultant(Fees), Investigator(Grants/Research Funding); Proscia – Investigator(Grants/Research Funding);
Jeffrey P. North, MD, FAAD
Johnson & Johnson Pharmaceutical Research & Development – Consultant (1099 relationship)(Fees);
Anisha Patel, MD, FAAD
Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); Chugai Pharmaceutical Co., Ltd – Speaker/Faculty Education(Other Financial Benefit); EMD Serono – Advisory Board(Fees); Erasca – Consultant (1099 relationship)(Fees); Hoth Therapeutics – Investigator(Grants/Research Funding); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); OnQuality Pharmaceuticals, Ltd. – Consultant(Fees), Investigator(Grants/Research Funding); Revolution Medicines – Advisory Board(Fees); Roche Pharma – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);
Karolyn Wanat, MD, FAAD
No financial relationships exist with ineligible companies.
Iwei Yeh, MD, PhD, FAAD
Pfizer Inc. – Investigator(Grants/Research Funding);